Imbruvica (ibrutinib)

May 4, 2020May 4, 2020

Cirmtuzumab-Imbruvica Yields ‘Encouraging’ Response Rates Against Mantle Cell Lymphoma, Ongoing Trial Shows

News

Combination therapy with the investigational treatment cirmtuzumab plus Imbruvica (ibrutinib) led to “highly encouraging” response rates among patients with mantle cell lymphoma (MCL), a type of B-cell cancer, according to the ... Read more

September 26, 2019

FDA Grants Abexinostat Fast Track Status for Follicular Lymphoma

News

Xynomic Pharmaceutical‘s abexinostat has received Fast Track Designation by the U.S. Food and Drug Administration (FDA) as a fourth-line treatment for follicular lymphoma, the company announced in a press release. ... Read more

August 8, 2019September 10, 2019

FDA Asked to Place Abexinostat, Possible Follicular Lymphoma Treatment, on Fast Track

News

Xynomic Pharmaceuticals has filed a request with U.S. Food and Drug Administration (FDA) asking that abexinostat, its lead therapeutic candidate for relapsed or refractory follicular lymphoma, be given fast track designation. The ... Read more

January 9, 2019January 31, 2019

First-line Imbruvica-Gazyva Therapy Extends Survival Without Disease Progression in CLL/SLL Patients, Phase 3 Study Shows

News

First-line treatment with Imbruvica (ibrutinib) plus Gazyva (obinutuzumab) significantly extends the time patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) live without cancer progression, and it also increases their ... Read more

November 5, 2018

Imbruvica Combo Improves Long-term Survival in CLL/SLL Patients, Updated Phase 3 Results Show

News

Combining AbbVie’s Imbruvica (ibrutinib) with Treanda (bendamustine) and Rituxan (rituximab) improves long-term survival outcomes in patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) whose cancer reappeared or ... Read more

October 23, 2018

FDA Grants Priority Review to Imbruvica-Gazyva Combo for First-line Treatment of CLL/SLL

News

The U.S. Food and Drug Administration has granted priority review to AbbVie‘s application seeking the approval of Imbruvica (ibrutinib) plus Gazyva (obinutuzumab) for patients with chronic lymphocytic leukemia or small lymphocytic ... Read more

July 2, 2018

Umbralisib Linked to Fewer Side Effects in Advanced Lymphoma and Leukemia Patients, Data Show

News

Umbralisib, an inhibitor of the PI3K delta protein, has a better long-term safety profile than equivalent treatments for advanced leukemia and lymphoma patients, those whose cancer failed to respond to multiple therapy ... Read more

February 23, 2018February 23, 2018

Imbruvica Only Moderately Effective in Relapsed Follicular Lymphoma Patients, Phase 2 Trial Shows

News

Imbruvica (ibrutinib) is only moderately effective against tumors in patients with relapsed follicular lymphoma, and certain clinical and genetic factors may have an impact on patient response, according to results ... Read more

October 31, 2017

Health Canada OKs Imbruvica for Treating Chronic Graft-Versus-Host Disease

News

Janssen‘s Imbruvica (ibrutinib) has been approved by Health Canada for treating chronic graft-versus-host disease (cGVHD), a life-threatening condition that some patients develop after a stem cell transplant. Following a priority ... Read more

September 19, 2017

UCSD Researchers Awarded $18.3M to Study New Combo Therapy for B-cell Cancers

News

The Independent Citizens Oversight Committee of the California Institute for Regenerative Medicine (CIRM) has aproved an $18.29 million grant to researchers at the University of California San Diego (UCSD) School ... Read more